The National Cancer Institute's (NCI) Office of Cancer Clinical Proteomics Research, part of the National Institutes of Health, and Korea University (KU) located in The Republic of Korea have signed a Memorandum of Understanding (MOU) in clinical proteogenomics cancer research. The MOU between NCI and KU represents the twenty-ninth institution and eleventh country to join the continued effort of the International Cancer Proteogenome Consortium (ICPC), an effort catalyzed through the vision of the 47th Vice President of the United States Joseph R. Biden, Jr. and the Cancer Moonshot. ICPC members apply the emerging science of proteogenomics, and have pledged to share their data with the public.
Announced during the HUPO2017 Global Leadership Gala Dinner in Dublin, Ireland on Saturday, September 16, the purpose of the MOU is to facilitate scientific and programmatic collaborations between NCI and KU in basic and clinical proteogenomic studies leading to patient care and public dissemination and information sharing to the research community. The scope of the collaboration requires NCI to assist KU in adopting and implementing the Clinical Proteomic Tumor Analysis Consortium (CPTAC) workflows as appropriate and to integrate innovative technologies in workflows based on pancreatic ductal adenocarcinoma, which is commonly diagnosed in South Korea. The MOU intends to enhance the understanding of proteogenomic complexity of tumors, facilitate the identification of treatments to use against a specific patient's tumor, and develop targeted multiplexed proteomic assays that consider population variation. Cooperation under this MOU is intended to leverage and maximize each entity's mission, current infrastructure, and research programs that advance the understanding of cancer and its treatment.
For more information on ICPC, click here.